LAUSR

Most pregnant patients who received nirmatrelvir–ritonavir treatment for mild-to-moderate coronavirus disease 2019 (COVID-19) tolerated treatment without adverse effects. This is a descriptive study of pregnant patients who received nirmatrelvir–ritonavir therapy from April 16, 2022, through May 18, 2022. Patients were eligible to receive nirmatrelvir–ritonavir if they were diagnosed with mild-to-moderate coronavirus disease 2019 (COVID-19) with symptom onset within 5 days, did not require oxygen therapy or hospital admission, and had no contraindications to nirmatrelvir–ritonavir. During the study time frame, 11 patients were identified as candidates for nirmatrelvir–ritonavir treatment. All patients agreed to nirmatrelvir–ritonavir treatment after a telehealth consultation; seven patients completed the treatment. All patients who received nirmatrelvir–ritonavir experienced symptom resolution without the need for additional care. All but one patient tolerated nirmatrelvir–ritonavir without immediate adverse effects, and no adverse fetal or neonatal effects were observed.